Do analysts prefer HVO or CIR?

hVIVO presently has a consensus target price of GBX 15, suggesting a potential upside of 133.14%. Given hVIVO's stronger consensus rating and higher probable upside, equities analysts plainly believe hVIVO is more favorable than Circassia Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Circassia Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend HVO or TILS?

hVIVO currently has a consensus target price of GBX 15, suggesting a potential upside of 133.14%. Given hVIVO's stronger consensus rating and higher possible upside, analysts clearly believe hVIVO is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate HVO or VSN?

hVIVO currently has a consensus price target of GBX 15, suggesting a potential upside of 133.14%. Given hVIVO's stronger consensus rating and higher possible upside, analysts clearly believe hVIVO is more favorable than Verseon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Verseon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, HVO or VSN?

hVIVO has higher revenue and earnings than Verseon. hVIVO is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 0.95 £17.84M -£0.87 N/A Verseon N/A N/A N/A -£14.30 N/A

Is HVO or VSN more profitable?

Verseon has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Verseon's return on equity of 0.00% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% Verseon N/A N/A N/A

Do analysts rate HVO or SCLP?

hVIVO presently has a consensus target price of GBX 15, suggesting a potential upside of 133.14%. Given hVIVO's stronger consensus rating and higher probable upside, equities analysts plainly believe hVIVO is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, HVO or SCLP?

hVIVO has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 0.95 £17.84M -£0.87 N/A Scancell £4.71M 21.33 -£6.75M -£0.55 N/A

Is HVO or SCLP more profitable?

hVIVO has a net margin of -12.48% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% Scancell -116.98% 90.29% -45.28%

Do analysts rate HVO or MPH?

hVIVO presently has a consensus price target of GBX 15, indicating a potential upside of 133.14%. Given hVIVO's stronger consensus rating and higher possible upside, equities analysts clearly believe hVIVO is more favorable than Mereo BioPharma Group plc (MPH.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Mereo BioPharma Group plc (MPH.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

hVIVO (HVO) Competitors

GBX 6.43 -0.07 (-1.02%)

As of 12:34 PM Eastern

Compare

HVO vs. CIR, TILS, VSN, SCLP, and MPH

Should you buy hVIVO stock or one of its competitors? hVIVO's main competitors and comparable companies include Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), and Mereo BioPharma Group plc (MPH.L) (MPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does hVIVO compare to Circassia Group?

hVIVO (LON:HVO) and Circassia Group (LON:CIR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

hVIVO has higher revenue and earnings than Circassia Group. hVIVO is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	0.95	£17.84M	-£0.87	N/A
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A

12.7% of hVIVO shares are owned by institutional investors. 4.9% of hVIVO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Circassia Group	Neutral

Circassia Group has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Circassia Group's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Circassia Group	N/A	N/A	N/A

hVIVO presently has a consensus target price of GBX 15, suggesting a potential upside of 133.14%. Given hVIVO's stronger consensus rating and higher probable upside, equities analysts plainly believe hVIVO is more favorable than Circassia Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Circassia Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

hVIVO beats Circassia Group on 7 of the 11 factors compared between the two stocks.

How does hVIVO compare to Tiziana Life Sciences?

hVIVO (LON:HVO) and Tiziana Life Sciences (LON:TILS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Tiziana Life Sciences has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Tiziana Life Sciences' return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Tiziana Life Sciences	N/A	N/A	N/A

hVIVO currently has a consensus target price of GBX 15, suggesting a potential upside of 133.14%. Given hVIVO's stronger consensus rating and higher possible upside, analysts clearly believe hVIVO is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tiziana Life Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.7% of hVIVO shares are held by institutional investors. 4.9% of hVIVO shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

hVIVO has higher revenue and earnings than Tiziana Life Sciences. hVIVO is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	0.95	£17.84M	-£0.87	N/A
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Tiziana Life Sciences'average media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Tiziana Life Sciences	Neutral

Summary

hVIVO beats Tiziana Life Sciences on 8 of the 11 factors compared between the two stocks.

How does hVIVO compare to Verseon?

hVIVO (LON:HVO) and Verseon (LON:VSN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Verseon has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Verseon's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Verseon	N/A	N/A	N/A

hVIVO currently has a consensus price target of GBX 15, suggesting a potential upside of 133.14%. Given hVIVO's stronger consensus rating and higher possible upside, analysts clearly believe hVIVO is more favorable than Verseon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Verseon	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

hVIVO has higher revenue and earnings than Verseon. hVIVO is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	0.95	£17.84M	-£0.87	N/A
Verseon	N/A	N/A	N/A	-£14.30	N/A

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Verseon	Neutral

12.7% of hVIVO shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

hVIVO beats Verseon on 8 of the 11 factors compared between the two stocks.

How does hVIVO compare to Scancell?

hVIVO (LON:HVO) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

hVIVO has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	0.95	£17.84M	-£0.87	N/A
Scancell	£4.71M	21.33	-£6.75M	-£0.55	N/A

hVIVO has a beta of 1.706, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Scancell has a beta of 0.687, indicating that its stock price is 31% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Scancell had 1 more articles in the media than hVIVO. MarketBeat recorded 1 mentions for Scancell and 0 mentions for hVIVO. Scancell's average media sentiment score of 0.49 beat hVIVO's score of 0.00 indicating that Scancell is being referred to more favorably in the news media.

Company	Overall Sentiment
hVIVO	Neutral
Scancell	Neutral

12.7% of hVIVO shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Comparatively, 15.5% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

hVIVO has a net margin of -12.48% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Scancell	-116.98%	90.29%	-45.28%

Summary

hVIVO beats Scancell on 10 of the 16 factors compared between the two stocks.

How does hVIVO compare to Mereo BioPharma Group plc (MPH.L)?

hVIVO (LON:HVO) and Mereo BioPharma Group plc (MPH.L) (LON:MPH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

hVIVO presently has a consensus price target of GBX 15, indicating a potential upside of 133.14%. Given hVIVO's stronger consensus rating and higher possible upside, equities analysts clearly believe hVIVO is more favorable than Mereo BioPharma Group plc (MPH.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Mereo BioPharma Group plc (MPH.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.7% of hVIVO shares are held by institutional investors. 4.9% of hVIVO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Mereo BioPharma Group plc (MPH.L)'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Mereo BioPharma Group plc (MPH.L)	Neutral

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A

hVIVO has higher revenue and earnings than Mereo BioPharma Group plc (MPH.L). hVIVO is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	0.95	£17.84M	-£0.87	N/A
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	-£128.00	N/A

Summary

hVIVO beats Mereo BioPharma Group plc (MPH.L) on 8 of the 11 factors compared between the two stocks.

Get hVIVO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HVO vs. The Competition

Export

Metric	hVIVO	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£44.29M	£4.06B	£7.40B	£2.92B
Dividend Yield	2.68%	3.61%	2.53%	6.17%
P/E Ratio	-7.40	11.42	272.19	367.32
Price / Sales	0.95	1,369.91	631.76	83,741.35
Price / Cash	4.94	108.37	79.89	27.89
Price / Book	1.16	16.88	13.14	7.02
Net Income	£17.84M	-£22.76M	£3.47B	£5.89B
7 Day Performance	-1.36%	1.55%	1.38%	0.89%
1 Month Performance	-14.21%	11.70%	8.62%	3.27%
1 Year Performance	-35.66%	56.88%	25.90%	22.28%

hVIVO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HVO hVIVO	N/A	GBX 6.43 -1.0%	GBX 15 +133.1%	-35.8%	£44.29M	£46.77M	N/A	N/A
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11
VSN Verseon	N/A	N/A	N/A	N/A	£112.24M	N/A	N/A	N/A	Gap Up
SCLP Scancell	N/A	GBX 9.50 -1.0%	N/A	-5.4%	£98.59M	£4.71M	N/A	51	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HVO) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

hVIVO (HVO) Competitors

HVO vs. CIR, TILS, VSN, SCLP, and MPH

How does hVIVO compare to Circassia Group?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Summary

How does hVIVO compare to Verseon?

Summary

How does hVIVO compare to Scancell?

Summary

How does hVIVO compare to Mereo BioPharma Group plc (MPH.L)?

Summary

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

hVIVO (HVO) Competitors

HVO vs. CIR, TILS, VSN, SCLP, and MPH

How does hVIVO compare to Circassia Group?

Which has better earnings & valuation, HVO or CIR?

Do institutionals and insiders have more ownership in HVO or CIR?

Does the media refer more to HVO or CIR?

Is HVO or CIR more profitable?

Do analysts prefer HVO or CIR?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Is HVO or TILS more profitable?

Do analysts recommend HVO or TILS?

Do insiders and institutionals hold more shares of HVO or TILS?

Which has better earnings & valuation, HVO or TILS?

Does the media prefer HVO or TILS?

Summary

How does hVIVO compare to Verseon?

Is HVO or VSN more profitable?

Do analysts rate HVO or VSN?

Which has better valuation and earnings, HVO or VSN?

Does the media refer more to HVO or VSN?

Do insiders & institutionals hold more shares of HVO or VSN?

Summary

How does hVIVO compare to Scancell?

Which has higher earnings & valuation, HVO or SCLP?

Which has more risk & volatility, HVO or SCLP?

Do analysts rate HVO or SCLP?

Does the media favor HVO or SCLP?

Do insiders and institutionals hold more shares of HVO or SCLP?

Is HVO or SCLP more profitable?

Summary

How does hVIVO compare to Mereo BioPharma Group plc (MPH.L)?

Do analysts rate HVO or MPH?

Do insiders and institutionals believe in HVO or MPH?

Does the media prefer HVO or MPH?

Is HVO or MPH more profitable?

Which has preferable valuation and earnings, HVO or MPH?

Summary

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools